Stock Monitor: Arrowhead Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / December 14, 2017 / Active-Investors issued a free report on TapImmune, Inc. (NASDAQ: TPIV), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=TPIV as the Company's latest news hit the wire. On December 12, 2017, the Company, which is a leading clinical-stage immuno-oncology Company with ongoing clinical trials in ovarian and breast cancer, declared that it has enrolled the first patient in the Phase-2 clinical trial of its novel therapeutic vaccine candidate TPIV200. The Company also shared that the study is fully funded by a $13.3 million grant from the US Department of Defense (DoD). Sign up now for our free research reports at:
www.active-investors.com/registration-sg
Active-Investors.com is currently working on the research report for Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), which also belongs to the Healthcare sector as the Company TapImmune. Do not miss out and become a member today for free to access this upcoming report at:
www.active-investors.com/registration-sg/?symbol=ARWR
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, TapImmune most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:
www.active-investors.com/registration-sg/?symbol=TPIV
About TPIV200
TPIV200 is a novel, multi-epitope, peptide-based cancer vaccine, which stimulates a memory T-cell immune response against the folate receptor alpha (FRa). FRa is the molecule that is overexpressed on the surface of the vast majority of triple-negative breast cancer (TNBC)'s cancer cells and is associated with cancer recurrence. TPIV200 induces both T ‘helper' cells and T ‘killer' cells to target tumor cells as it contains several carefully chosen FRa peptides. In fact, it covers more than 85% of human genotypes worldwide.
About the Phase-2 Trial
The Phase-2 trial is a randomized, multi-center, blinded, controlled trial. It would enroll 280 women with Stage Ib-IV TNBC who have completed initial surgery and radiotherapy/chemotherapy, prior to any disease recurrence.
The trial aims at comparing vaccination with TPIV200 plus an adjuvant (GM-CSF) with a control group that gets GM-CSF alone. In the study, patients would be administered six monthly injections of their assigned treatment regimen for the first six months. Following that, they would be given booster doses every six months.
Apart from the safety monitoring, the primary efficacy endpoint is disease-free survival of TPIV200-vaccinated patients compared to that of control patients.
Additionally, TapImmune, along with its clinical partners, is evaluating TPIV200 in multiple ongoing Phase-2 trials for treating ovarian and breast cancer, including a randomized dosing trial in TNBC that recently completed patient enrollment. The four-arm trial intends to help define the optimal TPIV200 vaccine dose and regimen to maximize patients' anti-tumor immune responses. The interim immunogenicity results from this ongoing study are expected in the first half of 2018.
Funding Worth $13.3 Million from US DoD
The Phase-2 trial, which is sponsored by Mayo Clinic, received a grant of $13.3 million from the US Department of Defense to gauge the prevention of cancer recurrence in women with TNBC who have already completed first-line surgery and radiotherapy/chemotherapy.
The grant from the US DoD would be given to Keith L. Knutson, Ph.D., Professor of Immunology in the Department of Immunology, and Edith A. Perez, M.D., Professor of Medicine in the Division of Hematology and Oncology, both at Mayo Clinic's Florida campus in Jacksonville, Florida. Professors Knutson and Perez are jointly leading the Phase-2 trial. Mayo Clinic and Dr. Knutson also have financial interests in TapImmune for the TNBC treatment.
TPIV200 Expected to Fulfill Unmet Medical Need
Peter Hoang, President and Chief Executive Officer (CEO) at TapImmune, shared that TapImmune is grateful to the US DoD and Mayo Clinic for enabling the Company to gain important clinical safety and efficacy insight for TPIV200 under this grant.
He believes that TPIV200, as well as their other vaccine candidates, play a very important role in the existing immuno-oncology ecosystem by potentially fulfilling a medical need, which is not yet addressed by existing immunotherapies. While the current immunotherapies are known to work in only a small number of patients, TapImmune's vaccines are designed to produce broad-based, durable T-cell responses in the vast majority of patients. The improved clinical outcomes would ensure potential regulatory and commercial success. The Company intends to provide more updates as and when the exciting Phase-2 study progresses and enrolls more patients.
Stock Performance Snapshot
December 13, 2017 - At Wednesday's closing bell, TapImmune's stock advanced 3.56%, ending the trading session at $3.20.
Volume traded for the day: 50.61 thousand shares, which was above the 3-month average volume of 19.50 thousand shares.
Stock performance in the last month – up 18.52%; and previous three-month period – up 8.84%
After yesterday's close, TapImmune's market cap was at $33.70 million.
The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 0.3% at the end of the session.
Active-Investors:
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@active-investors.com
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Active-Investors
